Amaros announced the launch of its Interventional Glaucoma Network (IGN), a clinician-led initiative aimed at accelerating the generation of high-quality clinical and real-world evidence in glaucoma care. The Amaros IGN brings together leading experts in glaucoma and anterior segment surgery to support clinical research, outcomes intelligence, and real-world data generation. According to Amaros, by leveraging the capabilities of AmarosEngine, the network is designed to enable more rigorous study design, streamline patient identification and enrollment, and standardize the collection of outcomes data across a wide range of interventional procedures. Founding members of the IGN include internationally recognized leaders in the field: Iqbal “Ike” Ahmed, FRCSC Jason E. Bacharach, MD John P. Berdahl, MD Cathleen M. McCabe, MD “Interventional glaucoma is evolving rapidly, but the supporting evidence infrastructure hasn’t kept pace,” said Ben Toker, co-founder and President of Amaros. “Our IGN brings together the field’s most influential clinicians with the precision intelligence capabilities of AmarosEngine to help close that gap. The result should be faster learning, clearer outcomes, and more consistent evidence generation across interventional glaucoma.” At the core of the IGN is AmarosEngine, the company’s proprietary precision intelligence platform. The system integrates data from electronic health records, practice management systems, imaging platforms, and claims into a unified, structured ecosystem. Operating directly within clinical workflows, AmarosEngine delivers real-time, actionable insights across the continuum of eye care. The platform is designed to support a range of applications, including accelerating clinical trial enrollment, generating real-world evidence, and helping clinicians optimize treatment strategies based on comprehensive data analysis. “AmarosEngine was built to transform complex ophthalmic data into actionable clinical intelligence,” said Vartan Ghazarossian, PhD, co-founder and CEO of Amaros. “The launch of the Amaros IGN marks an important milestone in our expansion beyond retina into glaucoma and reinforces our commitment to rigorous, clinician-driven evidence generation.” Leadership Appointments In conjunction with the IGN launch, Amaros announced two senior leadership appointments to support its expanding clinical and strategic initiatives. Mark Packer, MD, has been named Chief Medical Officer (CMO). Dr. Packer brings extensive experience in anterior segment surgery, innovation, and clinical research, and will oversee clinical strategy, evidence program design, and medical affairs across Amaros’ growing portfolio. Jai Parekh, MD, joins as Chief Strategy Officer (CSO). A recognized leader in glaucoma care and healthcare strategy, Dr. Parekh will guide the company’s commercial strategy, strategic partnerships, and broader growth initiatives as Amaros continues to scale its platform and evidence programs.